The planned retirement is orderly with a six-month transition period and potential board retention, reducing immediate leadership risk. Monitor for any successor appointment for the President of R&D role and for the Board's decision on Dr. Kelsey's directorship. No trading catalyst from this filing.
RVMD drugs
RVMD drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 22 $165.81entry
- T+1 · 5mo ago +2.23%α +3.68% · $169.51
- T+5 · 5mo ago +16.17%α +16.62% · $192.62
- T+20 · 4mo ago +12.27%α +12.42% · $186.16
- T+60 · 2mo ago +23.55%α +21.80% · $204.86
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Revolution Medicines filed an 8-K announcing the planned retirement of President of R&D Steve Kelsey, effective January 4, 2027, with a transition to senior advisor starting July 1, 2026, and a contemplated board appointment. The filing also reports routine annual meeting results, including the election of two Class III directors and ratification of the auditor. No financial data or material business changes were disclosed.
Key Facts
- Steve Kelsey, M.D., President of Research and Development, intends to retire effective January 4, 2027.
- Dr. Kelsey will transition to Senior Advisor to the CEO from July 1, 2026, until retirement.
- The company contemplates appointing Dr. Kelsey to the Board of Directors upon his retirement, subject to Board approval.
- Annual meeting results: Alexis Borisy and Mark A. Goldsmith elected as Class III directors; PwC ratified as auditor; advisory say-on-pay approved.
Financial Impact
No financial impact from this filing.
Risk Factors
- Potential loss of key R&D leadership if transition does not proceed as planned.
- Successor not yet named, creating uncertainty in R&D pipeline execution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-276718 |
| Document: 0001193125-26-276718-index-headers.html | 0001193125-26-276718 |
| Document: 0001193125-26-276718-index.html | 0001193125-26-276718 |
| Document: 0001193125-26-276718.txt | 0001193125-26-276718 |
Track record
44 reports on RVMD
7 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 17 of 18 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers